PARP1 and Cachexia: Remarkably, during a 30-day (d) survival experiment post-MMS treatment (75 mg/kg, a dose slightly below the LD50 of AagTg mice), we observed that AagTg/Parp1−/− mice began to lose significant body weight (Figure 1A) and exhibited signs of severe disease, including lethargy, a hunched posture, and cachexia (losing ~20% of initial BW) by 15d post-MMS treatment; all AagTg/Parp1−/− mice succumb within 30d (Figure 1B-1C).